Katrina J. Church - 14 Mar 2022 Form 4 Insider Report for Bioventus Inc. (BVS)

Role: SVP & Chief Compliance Officer
Signature: /s/Anthony D'Adamio, Attorney-in-Fact
Issuer symbol: BVS
Transactions as of: 14 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 12 Apr 2023, 20:48:36 UTC
Next filing: 08 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	BVS	Class A Common Stock						10,353	14 Mar 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BVS	Stock Option (Right to Buy)	Award	$0	+37,385		$0.000000	37,385	14 Mar 2022	Class A Common Stock	37,385	$12.66	Direct	F1
transaction	BVS	Restricted Stock Units	Award	$0	+17,200		$0.000000	17,200	10 Apr 2023	Class A Common Stock	17,200		Direct	F2, F3
transaction	BVS	Stock Option (Right to Buy)	Award	$0	+44,800		$0.000000	44,800	10 Apr 2023	Class A Common Stock	44,800	$1.16	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options shall vest in four equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date.
F2	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F3	The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date.